Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 30 September 2022
Revised: 16 December 2022
Accepted: 17 December 2022
First Online: 26 December 2022
Declarations
:
: P. Tierney discloses no conflicts of interest or funding. A. Zekeridou has a patent pending for PDE10A-IgG and DACH1-IgG as biomarkers of paraneoplastic autoimmunity. She also has research funding from Roche/Genentech. She has consulted for Alexion pharmaceuticals; all consulting fees are payable to Mayo Clinic. She is also a consultant in the Mayo Clinic Neuroimmunology Laboratory that offers commercial testing for neural autoantibodies. O. Adam has consulted for Abbott Laboratories.
